UK markets closed
  • NIKKEI 225

    27,011.33
    -120.01 (-0.44%)
     
  • HANG SENG

    24,289.90
    +46.29 (+0.19%)
     
  • CRUDE OIL

    86.51
    +0.91 (+1.06%)
     
  • GOLD FUTURES

    1,815.40
    -37.10 (-2.00%)
     
  • DOW

    34,166.84
    -130.89 (-0.38%)
     
  • BTC-GBP

    27,554.45
    -10.00 (-0.04%)
     
  • CMC Crypto 200

    849.16
    -6.65 (-0.78%)
     
  • ^IXIC

    13,542.12
    +2.82 (+0.02%)
     
  • ^FTAS

    4,192.70
    +53.23 (+1.29%)
     

Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen

·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • OCGN
  • INO

Inovio Pharmaceuticals (NASDAQ: INO) and Ocugen (NASDAQ: OCGN) are two small biotechs that hope to win regulatory authorizations for COVID-19 vaccines in the not-too-distant future. In this Motley Fool Live video recorded on Nov. 10, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how these two COVID-19 contenders stack up against each other. Keith Speights: There are two companies that hope to market COVID-19 vaccines: Inovio and Ocugen.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting